NCT00596791

CompletedPhase 3

Ocular Signs and Symptoms in Glaucoma Patients Switched From...

Santen Oy Source

Compare

Other study identifiers

Sponsor study identifier

Santen-77552

Secondary identifiers

EudraCT number 2007-004872-37

Study Type

interventional

Estimated enrollment

150

Locations

1 country

Sites

1

Timeline

Study Start

January 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

July 2008

Actual (reported)

Study Completion

August 2008

Actual (reported)

Brief Summary

The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Estimated enrollment: 150 participants
Study completion date: August 2008
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 2008
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
January 8, 2008
Actual (reported)
First Posted
January 17, 2008
Actual (reported)
Primary Completion
July 2008
Actual (reported)
Study Completion
August 2008
Actual (reported)

Last Updated: January 12, 2009
Status Verified: January 2009
Last Update Submitted: January 9, 2009

Conditions

Ocular Hypertension Open-Angle Glaucoma

Outcome Measures

Primary Outcomes (1)

Change from screening in ocular symptoms and signs
at week 6 and 12

Secondary Outcomes (1)

Safety and Quality of life parameters.
From Screening (visit 1) to visits at week 2, 6 and 12.

Study Arms (1)

1 arm

OTHER

Open-lable study with one arm.

Drug: tafluprost

Interventions

tafluprostDrug

prostaglandine analoque

1 arm

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the patient has been using latanoprost 0.005% as his/her prior medication. - Evaluable patients must have ocular surface related symptoms and/or signs with their prior medication.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Santen Oy
Industrylead

Study Sites (1)

Finn-Medi Research Oy

Tampere, 33520, Finland

MeSH Terms

Conditions

Ocular HypertensionGlaucoma, Open-Angle

Interventions

tafluprost

Condition Hierarchy (Ancestors)

Eye DiseasesGlaucoma

Study Officials

Hannu Uusitalo, Professor
Finn-Medi Research, Finland
PRINCIPAL INVESTIGATOR

Study Design

Study Type: interventional
Phase: phase 3
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

January 8, 2008

First Posted

January 17, 2008

Study Start

January 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

July 2008

Actual (reported)

NCT03204487

A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness

Phase 4Completed

NCT01342081

DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

Phase 3Completed

NCT01306461

Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations

Phase 3Completed

NCT01026831

Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)

Phase 3Completed

NCT00690794

Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3Completed

NCT00928590

Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3Completed

Study Completion

August 2008

Actual (reported)

Last Updated

January 12, 2009

Record last verified: 2009-01

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00596791
Data provider: ClinicalTrials.gov
Source updated: 2009-01-12
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:37:29 UTC

Locations

FI(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

1 arm

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

Locations